KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Current Assets (2017 - 2026)

Aquestive Therapeutics has reported Current Assets over the past 9 years, most recently at $149.3 million for Q4 2025.

  • For Q4 2025, Current Assets rose 69.2% year-over-year to $149.3 million; the TTM value through Dec 2025 reached $149.3 million, up 69.2%, while the annual FY2025 figure was $149.3 million, 69.2% up from the prior year.
  • Current Assets for Q4 2025 was $149.3 million at Aquestive Therapeutics, down from $151.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $151.7 million in Q3 2025 and troughed at $38.1 million in Q3 2022.
  • A 5-year average of $69.9 million and a median of $48.7 million in 2021 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: decreased 24.14% in 2022 and later skyrocketed 161.41% in 2024.
  • Year by year, Current Assets stood at $47.3 million in 2021, then decreased by 15.6% to $39.9 million in 2022, then grew by 2.7% to $41.0 million in 2023, then soared by 115.35% to $88.2 million in 2024, then skyrocketed by 69.2% to $149.3 million in 2025.
  • Business Quant data shows Current Assets for AQST at $149.3 million in Q4 2025, $151.7 million in Q3 2025, and $81.7 million in Q2 2025.